32700-48-4Relevant academic research and scientific papers
Cyclotriol derivative and production method and application thereof
-
Paragraph 0198; 0200; 0203; 0204, (2019/09/13)
The invention discloses a cyclotriol derivative and a production method and application thereof. The cyclotriol derivative is of a structure as shown in a general formula I, wherein R1, R2 and R3 areOH or AcNH; R1=OH, and R2=R3=AcNH or R2=OH, and R1=R3=AcNH or R3=OH, and R1=R2=AcNH; * stands for R configuration or S configuration; and Ac stands for caffeoyl CAc or derivatives caffesulfonyl SAc and caffe(mono-methyl ester)phosphonyl PAc of the caffeoyl CAc. According to the production method of the cyclotriol derivative, conditions are mild, automatic and industrial production are easy to achieve, operation is simple, convenient and safe, and the obtained cyclotriol derivative can act on anti-respiratory syncytial virus F protein, has high anti-RSV activity, low cell toxicity and high stability, can be used for producing medicines for treating virus infection, and is especially used for producing medicines for treating respiratory syncytial virus infection.
Inhibitors of influenza viruses replication
-
Page/Page column 385, (2016/06/14)
Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
INHIBITORS OF INFLUENZA VIRUSES REPLICATION
-
Paragraph 0989, (2016/10/08)
PROBLEM TO BE SOLVED: To provide inhibitors of influenza virus replication. SOLUTION: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient comprise administering to the biological sample or patient an effective amount of a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, where the values of structural formula (IA) are as described herein. A compound is represented by structural formula (IA) or a pharmaceutically acceptable salt thereof, where the values of structural formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle. COPYRIGHT: (C)2015,JPO&INPIT
INHIBITORS OF INFLUENZA VIRUSES REPLICATION
-
, (2012/07/14)
Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
o-benzenedisulfonimide as reusable bronsted acid catalyst for acid-catalyzed organic reactions
Barbero, Margherita,Cadamuro, Silvano,Dughera, Stefano,Venturello, Paolo
, p. 1379 - 1388 (2008/12/21)
Acid-catalyzed organic reactions, such as etherification, esterification, acetal synthesis, cleavage, and interconversion, and pinacol rearrangement were carried out in the presence of catalytic amounts of o-benzenedisulfonimide as Bronsted acid catalyst; the conditions were mild and selective. The catalyst was easily recovered and purified, ready to be used in further reactions, with economic and ecological advantages. Georg Thieme Verlag Stuttgart.
Synthesis of hexahydro-1H-benzo[c]chromen-1-amines via the intramolecular ring-opening reactions of aziridines by π-nucleophiles
Pulipaka, Aravinda B.,Bergmeier, Stephen C.
, p. 1420 - 1430 (2008/12/21)
The intramolecular cyclization of aziridines with π-nucleophiles can be a useful route to a number of heterocyclic and carbocyclic systems. This methodology has been applied to the synthesis of hexahydro-1H-benzo[c]chromen-1- amines, the basic skeleton of many amaryllidaceae alkaloids. The success of the aziridine cyclization is largely dependent on the N-substitution of aziridine, with activated aziridines not undergoing the cyclization reaction. Only N-H-, N-alkyl- and N-arylaziridines underwent the cyclization reaction. The ring opening of an unactivated aziridines with a π-nucleophile is one of the first examples of such a reaction. Georg Thieme Verlag Stuttgart.
Deoxygenated phosphorothioate inositol phosphate analogs: Synthesis, phosphatase stability, and binding affinity
Liu, Xiaodan,Moody, Emily C.,Hecht, Stephen S.,Sturla, Shana J.
, p. 3419 - 3427 (2008/09/20)
Inositol phosphates, such as 1d-myo-Inositol 1,4,5-trisphosphate [Ins(1,4,5)P3], are cellular second messengers with potential roles in cancer prevention and therapy. It typically is difficult to attribute specific pharmacological activity to a single inositol phosphate because they are rapidly metabolized by phosphatases and kinases. In this study, we have designed stable analogs of myo-inositol 4,5-bisphosphate [Ins(4,5)P2] and Ins(1,4,5)P3 that retain the cyclohexane scaffold, but lack hydroxyl groups that might be phosphorylated and have phosphate groups replaced with phosphatase-resistant phosphorothioates. An Ins(1,4,5)P3 analog, 1d-2,3-dideoxy-myo-inositol 1,4,5-trisphosphorothioate, was synthesized from (-)-quebrachitol, and an Ins(4,5)P2 analog, 1d-1,2,3-trideoxy-myo-inositol 4,5-bisphosphorothioate, was prepared from cyclohexenol. The Ins(1,4,5)P3 analog was recognized by Ins(1,4,5)P3 receptor with a binding constant (Kd) of 810 nM, compared with 54 nM for the native ligand Ins(1,4,5)P3, and was resistant to dephosphorylation by alkaline phosphatase under conditions in which Ins(1,4,5)P3 is extensively hydrolyzed. Analogs developed in this study are potential chemical probes for understanding mechanisms of inositol phosphate actions that may be elucidated by eliciting specific and prolonged activation of the Ins(1,4,5)P3 receptor.
Ring-closure metathesis in supercritical carbon dioxide as sole solvent with use of covalently immobilized ruthenium catalysts
Michalek, Florian,Maedge, Daniel,Ruehe, Juergen,Bannwarth, Willi
, p. 577 - 581 (2007/10/03)
We describe RCM reactions in the presence of a Hoveyda-type catalyst covalently immobilized on different support materials. The performance of the catalyst was highly dependent on the nature of the support, and in some cases high levels of conversion were
The activity of covalently immobilized Grubbs-Hoveyda type catalyst is highly dependent on the nature of the support material
Michalek, Florian,M?dge, Daniel,Rühe, Jürgen,Bannwarth, Willi
, p. 5172 - 5180 (2007/10/03)
A Hoveyda-type catalyst for olefin metathesis was synthesized and covalently attached via an amide bond to four different solid supports. One of these supports was a home-made hybrid silica support, where an ultra-thin copolymer of poly(styrene) and poly(acrylamide) was grafted on. The three other supports were commercially available, namely HypoGel 400, PEGA and Trisoperl. It was demonstrated that the catalysts were active in ring closing metathesis (RCM) reactions as well as in cross metathesis (CM) and ring opening metathesis (ROM) reactions, but the activity of the catalyst was highly dependent on the nature of the support.
Application of a Grubbs-Hoveyda metathesis catalyst noncovalently immobilized by fluorous-fluorous interactions
Michalek, Florian,Bannwarth, Willi
, p. 1030 - 1037 (2007/10/03)
A Grubbs-Hoveyda metathesis catalyst bearing a tris(perfluoroalkyl)silyl tag for efficient noncovalent attachment to fluorous silica gel (FSG) was synthesized and employed in ring-closing metathesis (RCM) reactions in CH 2Cl2. After
